arrow
M

Matthew C. Franklin

regeneron pharmaceuticals
H指数:32
被引数:7,907

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)

使用作用机制不同的FXI/FXIa抗体amrecibart(REGN9933A2)和cenvacibart(REGN7508Cat)进行抗凝

Blood
IF23.1
2026-06-150
OAAI
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo

基于全人源T细胞受体模拟抗体的CAR T细胞在体内表现出强大的抗肿瘤活性。

2025-03-260
PRE
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding
2023-06-212
OAAI
Blocking common ? chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models
2023-01-117
PRE
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2021-07-2629
OAAI
NMIHBA results from hypomorphic PRUNE1 variants that lack short-chain exopolyphosphatase activity
2020-10-2614
OAAI
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models
2020-03-1326
OAAI
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties
2019-12-264
OAAI